Does Lowering Inflammation Prevent a Heart Attack?

The question behind the headline

Can a medicine that lowers inflammation actually prevent a heart attack?

You may have seen the headlines about Reta. The research is interesting. But before we turn a better blood test into a promise about your heart, let's walk through what happens inside the body.

This is HEART RESERVE. I'm Lisa, a physician assistant and founder of HEART RESERVE. Today we're connecting inflammation, belly fat, blood sugar, and heart attacks, in language you don't need medical training to understand.

What inflammation means

Inflammation is part of how your body protects and repairs itself. If you cut your finger, immune cells help fight germs and begin healing. That response is useful.

Trouble can develop when the response lasts too long and starts damaging healthy tissue.

Fat tissue can be part of that process. The fat deep inside your abdomen, around your organs, is called visceral fat. In excess, it can release more inflammatory signals. Some of those signals are called cytokines. Think of them as messages that immune cells send to one another.

Those signals can also interfere with insulin. Insulin is the hormone that helps your body move sugar from the blood into cells. When cells respond less well, that's insulin resistance. Blood sugar may rise.

This is biology, not a judgment about someone's body. Weight and health are influenced by many things, and a person's appearance cannot tell you their complete heart risk.

The brain, liver, and kidneys

Let's connect this to your brain, liver, and kidneys.

Inflammation can contribute to liver injury. Your liver helps process nutrients and manage energy. In some people, fat buildup in the liver comes with inflammation and scarring.

Your kidneys filter your blood. Inflammatory diseases can injure those filters.

Inflammation in the brain or nervous system is called neuroinflammation. Researchers study its role in several diseases.

These are separate conditions with different causes. Finding less inflammation in someone's blood does not tell us that every organ has healed. You need evidence for the particular organ and illness you're talking about.

How plaque becomes a heart attack

Now let's bring it to the heart.

Your heart muscle needs a steady supply of oxygen-rich blood. Small arteries called coronary arteries deliver it.

Over time, cholesterol and other material can collect within an artery wall. That collection is called plaque. The disease is called atherosclerosis.

Inflammation can contribute to plaque growth and weaken the covering over it.

If that covering breaks open, blood comes into contact with material inside the plaque. A clot can form at that spot. If the clot blocks the artery, part of the heart muscle loses its oxygen supply and begins to die. That's one common way a heart attack happens.

So the problem isn't only how narrow an artery has become. Whether a plaque stays stable matters too.

There are other causes of heart attacks. This explains a common pathway, not every person's situation.

What the Reta study showed

Where does Reta fit?

It's short for retatrutide, an experimental medicine that acts on three hormone signals involved in appetite and how the body uses energy.

Researchers went back through two earlier trials to look for changes in blood tests. The analysis was published in twenty twenty-six and funded by Lilly, the company developing the medicine.

One test was CRP. That's a protein your liver makes in response to inflammation. The test cannot tell you where the inflammation is or what's causing it.

Among adults with obesity or overweight, without diabetes, one study dose lowered CRP by about fifty-five percent over forty-eight weeks. With a shot containing no active medicine, it fell about eight percent. Both numbers describe changes from where each group started.

Another inflammation blood test and some cholesterol measures improved too. The separate diabetes trial did not show a clear benefit for the inflammation blood tests.

These findings did not prove fewer heart attacks or protection of the brain, liver, or kidneys. Researchers also couldn't tell how much of the change was explained by weight loss.

A fifty-five percent drop in CRP does not mean fifty-five percent fewer heart attacks.

As of October fifth, twenty twenty-six, Reta is not FDA approved.

Can treating inflammation protect the heart?

Have researchers tested whether treating inflammation can protect the heart? They have.

In a trial called CANTOS, more than ten thousand people who had already had a heart attack and had high inflammation levels received an inflammation-targeting medicine or an inactive treatment.

At one dose, the medicine reduced the number of heart attacks, strokes, and deaths from heart or blood vessel problems, counted together. It did this without lowering cholesterol.

That showed that treating a specific part of the body's inflammation response can help some people who have already had a heart attack.

But serious infections that caused death were more common with the medicine. And when researchers counted deaths from every cause, there wasn't a clear difference.

So we can't assume that every treatment advertised as anti-inflammatory protects the heart, or that reducing inflammation is always safe. The exact medicine and the people taking it matter.

A weight-loss medicine with heart-outcome evidence

Another trial, called SELECT, tested whether a weight-loss medicine could reduce heart attacks, strokes, or deaths from heart and blood vessel problems.

It studied semaglutide, the medicine in Wegovy. More than seventeen thousand adults took part. They were at least forty-five, had overweight or obesity, and already had disease affecting their heart or blood vessels. They did not have diabetes.

Over an average of about three years and four months, roughly sixty-five out of every thousand people taking semaglutide had one of those serious problems. With the inactive treatment, about eighty out of a thousand did.

That's about fifteen fewer people out of a thousand during the study.

More people stopped semaglutide because of side effects.

These results apply to semaglutide in those patients. They don't prove the same benefit for Reta, and they don't show that reducing inflammation alone caused the improvement.

What to do with this information

What does this mean at your next appointment?

Start with your own risk. Ask: What do my blood pressure, cholesterol, blood sugar, smoking history, and family history tell us? Then ask: Which changes or treatments have been shown to help someone like me?

Regular movement, a heart-healthy eating pattern, enough sleep, and avoiding tobacco all belong in that conversation. Medicines may belong there too. You don't have to choose between healthy habits and appropriate medical treatment.

If an inflammation test is being considered, ask what the result would change. The goal is a useful decision, not simply collecting another number.

When you hear about a new medicine, ask who was studied, what actually improved, and what side effects occurred.

That's how we move from an exciting headline to a decision that makes sense for you.

I'm Lisa, and this is HEART RESERVE. Your health history matters to your heart. Know your story. Build your reserve.